These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38490995)

  • 21. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
    Geer MI; Koul PA; Tanki SA; Shah MY
    J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of pharmacogenetics of adverse drug reactions in elderly people.
    Cardelli M; Marchegiani F; Corsonello A; Lattanzio F; Provinciali M
    Drug Saf; 2012 Jan; 35 Suppl 1():3-20. PubMed ID: 23446782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).
    Picard N; Boyer JC; Etienne-Grimaldi MC; Barin-Le Guellec C; Thomas F; Loriot MA;
    Therapie; 2017 Apr; 72(2):185-192. PubMed ID: 28237406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department.
    Kauppila M; Backman JT; Niemi M; Lapatto-Reiniluoto O
    Eur J Clin Pharmacol; 2021 Apr; 77(4):643-650. PubMed ID: 33188450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.
    Mhandire DZ; Goey AKL
    Mol Diagn Ther; 2022 Mar; 26(2):137-151. PubMed ID: 35113367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
    Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
    Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation.
    Turongkaravee S; Jittikoon J; Rochanathimoke O; Boyd K; Wu O; Chaikledkaew U
    BMC Health Serv Res; 2021 Oct; 21(1):1042. PubMed ID: 34600523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.
    Cacabelos R; Naidoo V; Corzo L; Cacabelos N; Carril JC
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementing comprehensive pharmacogenomics in a community hospital-associated primary care setting.
    Wick JA; Schmidlen T; Grande K; Moretz C; Ashcraft K; Green J; Moyer N; Blaxall BC
    J Am Pharm Assoc (2003); 2023; 63(1):188-192. PubMed ID: 36243653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients.
    Lteif C; Eddy E; Terrell J; Cavallari LH; Malaty J; Duarte JD
    Clin Transl Sci; 2024 Jan; 17(1):e13692. PubMed ID: 38013396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are we PREPAREd? Concerning the "PREemptive Pharmacogenomics Testing for Preventing Adverse Drug Reactions (PREPARE) Study".
    De Carmo Campos A; Cardoso ML; Vicente A
    Acta Med Port; 2023 Oct; 36(10):689-690. PubMed ID: 37788651
    [No Abstract]   [Full Text] [Related]  

  • 32. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study.
    Wu C; Bell CM; Wodchis WP
    Drug Saf; 2012 Sep; 35(9):769-81. PubMed ID: 22823502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center.
    Leary E; Brilliant M; Peissig P; Griesbach S
    Am J Health Syst Pharm; 2019 Feb; 76(6):387-397. PubMed ID: 31415684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenomic considerations for medications in the perioperative setting.
    Jhun EH; Apfelbaum JL; Dickerson DM; Shahul S; Knoebel R; Danahey K; Ratain MJ; O'Donnell PH
    Pharmacogenomics; 2019 Jul; 20(11):813-827. PubMed ID: 31411557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenomics of off-target adverse drug reactions.
    Garon SL; Pavlos RK; White KD; Brown NJ; Stone CA; Phillips EJ
    Br J Clin Pharmacol; 2017 Sep; 83(9):1896-1911. PubMed ID: 28345177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-emptive pharmacogenomics implementation among polypharmacy patients 65 years old and older: a clinical pilot.
    Uber R; Hayduk VA; Pradhan A; Ward T; Flango A; Graham J; Wright EA
    Pharmacogenomics; 2023 Dec; 24(18):915-920. PubMed ID: 37965783
    [No Abstract]   [Full Text] [Related]  

  • 38. Prevention of adverse drug effects: a pharmacogenomic approach.
    Scott EN; Hasbullah JS; Carleton BC; Ross CJD
    Curr Opin Pediatr; 2020 Oct; 32(5):646-653. PubMed ID: 32796162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Pharmacogenetic Drugs by the Dutch Population.
    Alshabeeb MA; Deneer VHM; Khan A; Asselbergs FW
    Front Genet; 2019; 10():567. PubMed ID: 31312209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions].
    Mushiroda T
    Nihon Yakurigaku Zasshi; 2024; 159(2):90-95. PubMed ID: 38432925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.